Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study

Abstract

Plain Language Summary Psoriatic disease is a group of heterogeneous inflammatory conditions, mainly affecting patients’ skin and joints. Among the few biomarkers associated with inflammation in psoriatic disease, serum calprotectin may be a promising one. Therefore, we conducted a longitudinal study to explore the clinical significance of calprotectin in patients with psoriatic arthritis at Peking University First Hospital. We found that the level of serum calprotectin positively correlated with disease activity parameters and scores in psoriatic arthritis. It also possessed the ability to predict the achievement of treatment targets, including remission and minimal disease activity. On the basis of the findings of our study, we reckon that CLP may be a useful tool in clinical work.

Keywords

• Psoriatic arthritis
• Calprotectin
• Disease activity
• Remission
• Minimal disease activity